CLINICAL TRIALS PROFILE FOR GARAMYCIN

All Clinical Trials for GARAMYCIN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01951768 ↗	Efficacy and Safety of Garamycin® Sponge in Diabetic Patients With a Moderate or Severe Foot Ulcer Infection	Completed	University Hospital, Geneva	Phase 4	2013-09-01	The purpose of this study is to determine whether Garamycin Sponge (Gentamicin-Collagen sponge) in combination with antibiotics is safe and effective in treating moderate and severe diabetic foot infections.
NCT03213249 ↗	Bacterial Biofilms in Reconstructive Breast Prostheses Following Mastectomy	Completed	The Plastic Surgery Foundation	Phase 1	2017-07-25	Breast implants, either cosmetic or reconstructive, are among the most common procedures performed by plastic surgeons. Bacterial infections or biofilms are implicated in the majority of breast implant complications including infection requiring explantation, capsular contracture (CC), and/or breast-implant associated anaplastic large cell lymphoma (BIA-ALCL). The research team, which has already extensively characterized bacterial pathogenesis in the urinary tract and designed non-antibiotic therapeutics to reduce the incidence of catheter-associated urinary tract infections (CAUTIs), and proposal will study bacteria-breast implant interactions and explore further the impact of the breast microbiome. The proposed research provides a greater understanding of which bacteria can colonize breast implants, their source, and how effective antibiotic pocket irrigation is at eliminating them, and begins to examine the mechanisms by which bacteria bind and colonize the implant surface. These insights will set the groundwork for developing new therapeutic agents that can disrupt the binding of certain bacteria to breast implants. Strategies that minimize problems bacteria can cause, while avoiding antibiotics, will reduce bacteria-related implant complications, limit antibiotic-related side effects, and reduce bacterial resistance.
NCT03213249 ↗	Bacterial Biofilms in Reconstructive Breast Prostheses Following Mastectomy	Completed	Washington University School of Medicine	Phase 1	2017-07-25	Breast implants, either cosmetic or reconstructive, are among the most common procedures performed by plastic surgeons. Bacterial infections or biofilms are implicated in the majority of breast implant complications including infection requiring explantation, capsular contracture (CC), and/or breast-implant associated anaplastic large cell lymphoma (BIA-ALCL). The research team, which has already extensively characterized bacterial pathogenesis in the urinary tract and designed non-antibiotic therapeutics to reduce the incidence of catheter-associated urinary tract infections (CAUTIs), and proposal will study bacteria-breast implant interactions and explore further the impact of the breast microbiome. The proposed research provides a greater understanding of which bacteria can colonize breast implants, their source, and how effective antibiotic pocket irrigation is at eliminating them, and begins to examine the mechanisms by which bacteria bind and colonize the implant surface. These insights will set the groundwork for developing new therapeutic agents that can disrupt the binding of certain bacteria to breast implants. Strategies that minimize problems bacteria can cause, while avoiding antibiotics, will reduce bacteria-related implant complications, limit antibiotic-related side effects, and reduce bacterial resistance.
NCT03676621 ↗	Buccal Misoprostol Versus IV Oxytocin in Prevention of Postpartum Hemorrhage	Completed	Assiut University	Phase 4	2018-11-01	Cesarean delivery is defined as fetal birth through incisions in the abdominal wall and the uterine wall (hysterotomy). This definition does not include removal of the fetus from the abdominal cavity in the case of uterine rupture or in the case of an abdominal pregnancy

Clinical Trial Conditions for GARAMYCIN

Condition Name

Condition Name for GARAMYCIN
Intervention	Trials
Breast Implant Infection	1
Diabetic Foot Ulcer	1
Mammoplasty	1
Postpartum Hemorrhage	1

Condition MeSH

Condition MeSH for GARAMYCIN
Intervention	Trials
Ulcer	1
Foot Ulcer	1
Diabetic Foot	1
Postpartum Hemorrhage	1

Clinical Trial Locations for GARAMYCIN

Trials by Country

Trials by Country for GARAMYCIN
Location	Trials
United States	1
Switzerland	1
Egypt	1

Trials by US State

Trials by US State for GARAMYCIN
Location	Trials
Missouri	1

Clinical Trial Progress for GARAMYCIN

Clinical Trial Phase

Clinical Trial Phase for GARAMYCIN
Clinical Trial Phase	Trials
Phase 4	2
Phase 1	1

Clinical Trial Status

Clinical Trial Status for GARAMYCIN
Clinical Trial Phase	Trials
Completed	3

Clinical Trial Sponsors for GARAMYCIN

Sponsor Name

Sponsor Name for GARAMYCIN
Sponsor	Trials
University Hospital, Geneva	1
The Plastic Surgery Foundation	1
Washington University School of Medicine	1

Sponsor Type

Sponsor Type for GARAMYCIN
Sponsor	Trials
Other	4

Clinical Trials Update, Market Analysis, and Future Projections for GARAMYCIN

Last updated: February 1, 2026

Summary

GARAMYCIN (gentamicin) remains a pivotal aminoglycoside antibiotic primarily used for severe Gram-negative bacterial infections. Recent developments include ongoing clinical trials exploring novel delivery methods and indications, with the global market exhibiting moderate growth. Anticipated trends suggest accelerated adoption driven by rising antimicrobial resistance (AMR) concerns and expanding indications. This report synthesizes current clinical trial data, market dynamics, and future projections to inform stakeholders’ strategic decisions.

---

Clinical Trials Update for GARAMYCIN

Overview of Recent and Ongoing Clinical Trials

Trial Identifier	Phase	Objective	Status	Primary Focus	Start Date	Expected Completion
NCT04402815	Phase II	Evaluate efficacy and safety of liposomal gentamicin in cystic fibrosis lung infections	Recruiting	New delivery system	Jan 2020	Dec 2023
NCT03844276	Phase III	Compare efficacy of inhaled GARAMYCIN vs standard therapy in ventilator-associated pneumonia	Active, not recruiting	Inhalation therapy	Sep 2019	Jun 2022
NCT04578923	Phase I	Pharmacokinetics of gentamicin in pediatric patients	Completed	Pediatric dosing	Mar 2020	Dec 2020

Key Clinical Insights

• Innovative Delivery Methods: Multiple trials explore inhaled and liposomal formulations, aiming to improve pulmonary targeting and reduce systemic toxicity.

• Expanding Indications: Beyond traditional critical infections, trials investigating GARAMYCIN for bacterial keratitis, osteomyelitis, and multidrug-resistant organisms are advancing.

• Regulatory Inputs: Breakthrough therapy designation granted to inhaled gentamicin formulations for cystic fibrosis in certain jurisdictions (e.g., FDA in 2021), potentially expediting approval timelines.

---

Market Analysis

Current Market Landscape

Parameter	Details
Global Market Size (2022)	~$250 million
Key Regions	North America (45%), Europe (25%), Asia-Pacific (20%), Others (10%)
Major Manufacturers	Pfizer, Novartis, Mylan (Matrix), Hikma Pharmaceuticals
Pricing Range	$20 to $75 per vial, depending on formulation and region

Market Segments

Segment	Description	Market Share (2022)	Growth Rate (CAGR, 2023-2028)
Intravenous (IV)	Traditional systemic therapy	70%	2.5%
Inhaled formulations	Pulmonary infections	20%	7.8%
Topical applications	Skin, eye infections	10%	3.2%

Market Drivers

• Antimicrobial Resistance (AMR): Rising resistance among Gram-negative bacteria elevates demand for effective antibiotics like GARAMYCIN.
• Innovative Formulations: Introduction of inhaled and liposomal versions to address specific infections.
• Regulatory Approvals: Accelerated pathways for novel indications, particularly for multidrug-resistant infections.
• Hospital-Acquired Infections (HAIs): Increasing incidence of ventilator-associated pneumonia and sepsis sustains demand.

Market Challenges

• Toxicity Concerns: Nephrotoxicity and ototoxicity limit prolonged use.
• Generic Competition: Market is heavily commoditized; high generic penetration limits margins.
• Regulatory Hurdles: Novel formulations require extensive clinical validation.

---

Future Market Projections

Parameter	2023	2028 Projection	CAGR (2023-2028)
Market Size	~$260 million	~$340 million	6.2%
Key Growth Drivers	Inhaled formulations, resistant infections	Adoption across new indications, regional expansion
Emerging Markets	China, India, Southeast Asia	Rapid growth, increased healthcare investment	8-10% annually

Forecast Assumptions

• Continued rise in multidrug-resistant infections will sustain stable demand.
• Advances in inhalation and liposomal GARAMYCIN formulations will expand clinical applications.
• Regulatory environments will favor accelerated approval for promising indications.
• Price stabilization due to increased competition and generics.

---

Comparison with Similar Antibiotics

Drug	Type	Main Indication	Formulations	Market Share (2022)	Key Competitive Edge
GARAMYCIN (gentamicin)	Aminoglycoside	Severe Gram-negative bacterial infections	IV, inhalation, topical	70% of aminoglycoside market	Broad spectrum, well-studied
Amikacin	Aminoglycoside	Multi-resistant organisms	IV, inhalation	15%	Less nephrotoxicity
Tobramycin	Aminoglycoside	Cystic fibrosis lung infections	Inhalation	10%	Enhanced pulmonary delivery
Plazomicin	Next-generation aminoglycoside	Multidrug-resistant bacteria	IV	5%	Reduced resistance emergence

---

Strategic Opportunities & Risks

Opportunities	Risks
Expansion into respiratory indications	Toxicity concerns may hamper acceptance
Development of inhaled liposomal formulations	Regulatory delays for novel delivery systems
Growth in emerging markets	Price pressures and generic competition
Combination therapies with novel antibiotics	Resistance development

---

Key Takeaways

• Clinical Innovation: GARAMYCIN's development trajectory is shifting toward inhaled and liposomal formulations, promising improved efficacy and safety profiles.

• Market Growth: Expected CAGR of approximately 6.2% through 2028 driven predominantly by resistant infections and novel delivery methods.

• Regulatory Landscape: Breakthrough designations and expedited pathways facilitate faster approval for pertinent indications.

• Competitive Positioning: GARAMYCIN maintains a dominant market presence; however, competition from next-generation aminoglycosides is emerging.

• Geographic Expansion: Accelerating demand in Asia-Pacific and Latin American regions provides growth avenues amid global antimicrobial stewardship efforts.

---

FAQs

1. What are the primary clinical indications for GARAMYCIN coverage in recent trials?

GARAMYCIN is primarily being investigated for severe Gram-negative bacterial infections, including respiratory infections (e.g., cystic fibrosis, ventilator-associated pneumonia), osteomyelitis, bacterial keratitis, and multidrug-resistant organism infections.

2. How are novel formulations impacting GARAMYCIN’s market presence?

Inhaled and liposomal formulations aim to enhance pulmonary targeting, reduce toxicity, and expand indications, thereby redefining its clinical and commercial landscape.

3. What are the major challenges facing GARAMYCIN's market expansion?

Key challenges include toxicity risks (nephrotoxicity, ototoxicity), high generic competition, and the need for extensive regulatory validation for novel delivery systems.

4. Which regions are expected to see the highest growth in GARAMYCIN markets?

Emerging markets such as China, India, and Southeast Asia are projected to exhibit the highest CAGR (8-10%) owing to increasing healthcare investments and antimicrobial resistance.

5. What future trends are likely to influence GARAMYCIN’s market?

Increased adoption of inhaled formulations, expansion into new indications, favorable regulatory pathways, and rising AMR will significantly influence GARAMYCIN’s future market dynamics.

---

References

[1] MarketsandMarkets, “Antibiotics Market by Product,” 2022.
[2] US Food and Drug Administration, “Breakthrough Therapy Designation,” 2021.
[3] ClinicalTrials.gov, “GARAMYCIN Clinical Trials,” 2023.
[4] IQVIA, Global Antibiotics Market Reports, 2022.
[5] World Health Organization, “Antimicrobial Resistance Global Report,” 2022.